Analysts forecast that Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) will report $5.00 million in sales for the current quarter, according to Zacks. Three analysts have made estimates for Paratek Pharmaceuticals’ earnings. Paratek Pharmaceuticals reported sales of $30,000.00 during the same quarter last year, which indicates a positive year over year growth rate of 16,566.7%. The business is scheduled to issue its next quarterly earnings results on Thursday, March 1st.

On average, analysts expect that Paratek Pharmaceuticals will report full year sales of $5.00 million for the current year, with estimates ranging from $7.50 million to $15.00 million. For the next year, analysts expect that the business will post sales of $8.47 million per share, with estimates ranging from $50,000.00 to $22.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow Paratek Pharmaceuticals.

A number of equities analysts recently weighed in on the company. BidaskClub cut Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday. Zacks Investment Research raised Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, November 1st. Robert W. Baird reissued a “buy” rating and issued a $40.00 price target on shares of Paratek Pharmaceuticals in a research note on Tuesday, October 24th. Guggenheim assumed coverage on Paratek Pharmaceuticals in a research note on Tuesday, October 24th. They issued a “buy” rating and a $44.00 price target on the stock. Finally, Cantor Fitzgerald set a $50.00 price target on Paratek Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, October 17th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Paratek Pharmaceuticals has an average rating of “Buy” and a consensus price target of $40.00.

Large investors have recently added to or reduced their stakes in the business. Cadence Capital Management LLC purchased a new position in Paratek Pharmaceuticals during the 2nd quarter valued at about $562,000. Royce & Associates LP grew its stake in Paratek Pharmaceuticals by 113.3% during the 2nd quarter. Royce & Associates LP now owns 282,900 shares of the specialty pharmaceutical company’s stock valued at $6,818,000 after acquiring an additional 150,300 shares in the last quarter. Marshall Wace LLP purchased a new position in Paratek Pharmaceuticals during the 2nd quarter valued at about $942,000. Alps Advisors Inc. purchased a new position in Paratek Pharmaceuticals during the 2nd quarter valued at about $598,000. Finally, C WorldWide Group Holding A S grew its stake in Paratek Pharmaceuticals by 46.8% during the 3rd quarter. C WorldWide Group Holding A S now owns 645,100 shares of the specialty pharmaceutical company’s stock valued at $16,192,000 after acquiring an additional 205,700 shares in the last quarter. 84.30% of the stock is currently owned by institutional investors.

Paratek Pharmaceuticals (NASDAQ:PRTK) opened at $18.65 on Monday. Paratek Pharmaceuticals has a 12 month low of $12.90 and a 12 month high of $29.00. The company has a quick ratio of 10.53, a current ratio of 10.53 and a debt-to-equity ratio of 0.49.

ILLEGAL ACTIVITY WARNING: This report was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/12/04/5-00-million-in-sales-expected-for-paratek-pharmaceuticals-inc-prtk-this-quarter-2.html.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Get a free copy of the Zacks research report on Paratek Pharmaceuticals (PRTK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.